9月14日，美敦力盘中上涨3.03%，报93.395美元/股，成交额1.75亿美元。消息面上，伯恩斯坦将美敦力目标价从105美元上调至112美元，维持跑赢大盘评级，当前华尔街平均目标价约104美元。
同日，美敦力正式发起换股要约，拟剥离前糖尿病业务部门MiniMed至少80.1%的股份。根据要约条款，股东可以7%的折价将美敦力普通股转换为MiniMed股票，每股美敦力最多可换取4.5939股MiniMed，显示公司在业务分拆上的推进力度。
基本面上，美敦力此前公布的FY27 Q1业绩超预期，营收同比增长13.8%至97.6亿美元，心血管业务大增18.9%，全年调整后EPS指引上调至5.94至6.00美元。多家机构在财报后密集上调目标价，基本面改善与资本运作双轮驱动构成本次上行支撑。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.